November 18, 2009 - Pre-hospital Cardiac Arrest Resuscitation and Survival Rates Increase


A. Ernest Whiton
Chief Financial Officer
ZOLL Medical Corporation
+1 (978) 421-9655


Diane Egan
ZOLL Medical Corporation
+1 (978) 421-9637


ZOLL Products Contribute to Significant Improvement

November 18, 2009CHELMSFORD, MASS.– ZOLL Medical Corporation (Nasdaq GS: ZOLL) announced today that in a “Best Original Resuscitation Science” presentation at the American Heart Association’s Resuscitation Science Symposium (ReSS) in Orlando Florida, Joseph P. Ornato, M.D., and Mary Ann Peberdy, M. D., reported nearly  doubling the resuscitation and survival rates from out-of-hospital cardiac arrest due to a comprehensive treatment protocol established between Virginia Commonwealth University Medical Center (VCU) and the Richmond Ambulance Authority (RAA).  

The authors reported an improvement in the return of spontaneous circulation (ROSC) from 25 percent in 2001 to 46 percent in 2008. In addition, the survival to hospital discharge rate, with a national average less than 7 percent, increased from 9.7 percent in 2003 to 17.9 percent at the end of 2008. A second study looking only at hospital admissions, also presented by Drs. Ornato and Peberdy at ReSS, showed the survival rate to hospital discharge improving from 19 percent in 2001-2003 to 49 percent in 2008-2009 after implementation of this new treatment protocol.

Dr. Ornato, Chair of the Department of Emergency Medicine at VCU School of Medicine and Operational Medical Director of RAA, and Dr. Peberdy, Professor of Medicine and Emergency Medicine in the Division of Cardiology at VCU School of Medicine, noted the two goals of the initiative:

  • To restart the heart as quickly as possible following onset of cardiac arrest
  • To bring resuscitated patients to a single specialized post-resuscitation facility. 

Both programs utilize advanced technology found in ZOLL products. These include the ZOLL AutoPulse®, a revolutionary non-invasive cardiac support pump, the ZOLL Intravascular Temperature Management (IVTM™) system, and the E Series® Monitor Defibrillators. 

  • The AutoPulse was used both in the pre-hospital and hospital settings to provide consistent, uninterrupted chest compressions resulting in blood flow during SCA that is simply not possible with human hands. 
  • ZOLL's IVTM gives health care providers the power and control they need to rapidly, safely, and effectively manage the core body temperature of critically ill or surgical patients.  All ZOLL patented catheter designs combine precise temperature management with the critical care functions of a standard central venous catheter.  
  • The E Series monitor defibrillators include Real CPR Help® real-time feedback and See-Thru CPR®, industry-unique filtering technology that allows clinicians to view a patient’s underlying cardiac rhythm by filtering CPR artifact during resuscitation efforts.

“We’re pleased that our technological innovations have been able to contribute to the improved survival rates reported by Drs. Ornato and Peberdy,” said Jonathan A. Rennert, President of ZOLL. “The VCU-RAA initiative clearly demonstrates the impact an alliance between a hospital and EMS agency can have in advancing resuscitation care.”    

About ZOLL Medical Corporation

ZOLL Medical Corporation develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies.  With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies which help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and critical care.

A NASDAQ Global Select company and a Forbes 100 Most Trustworthy Company for the past three years, ZOLL develops and manufactures its products in the United States, in California, Colorado, Illinois, Massachusetts, Pennsylvania, and Rhode Island. More than 400 direct sales and service representatives, 1,100 business partners, and 200 independent representatives serve our customers in over 140 countries around the globe. For more information, visit

Certain statements contained in this press release, including statements regarding the future business of the Company, and other statements contained herein regarding matters that are not historical facts, are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled “Risk Factors” in the Company's Quarterly Report on Form 10-Q filed with the SEC on August 7, 2009. You should not place undue reliance on the forward-looking statements in this press release, and the Company disavows any obligation to update or supplement those statements in the event of any changes in the facts, circumstances, or expectations that underlie those statements.

Copyright © 2009 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. ZOLL, AutoPulse, CodeNet, E Series, Real CPR Help, and See-Thru CPR are registered trademarks of ZOLL Medical Corporation. IVTM is a trademark of ZOLL Medical Corporation.  All product names are the property of their respective owners.